Shamburg News · 8-K filed Oct 13, 2026, 8:25 AM EDT

iBio Reports Preclinical NHP Data Showing IBIO-610 Preserves Muscle With Semaglutide

IBIO · iBio, Inc.

  • Other event
  • Reg FD disclosure
  • Materiality: medium

On October 13, 2026, iBio, Inc. issued a press release highlighting preclinical body-composition data from an eight-week obese non-human primate study of IBIO-610, a potential first-in-class Activin E antibody, discussed at the EASD Annual Meeting on October 1, 2026. Fat accounted for 93% of weight lost by NHPs given IBIO-610 with twice-weekly semaglutide, compared with 77% for semaglutide alone, and lean mass made up 6% versus 22%. The company plans to begin first-in-human studies of IBIO-610 in the first half of 2027.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 7.01, 8.01, 9.01, accession 0001420720-26-000030.

Written from the filing by Shamburg Markets. Figures are as reported by the company.